Is diclofenac potassium available over the counter in Canada for a perimenopausal woman with migraines?

Diclofenac Potassium Over-the-Counter Availability in Canada

Diclofenac potassium 12.5 mg tablets are available over-the-counter (without prescription) in Canada for the treatment of mild to moderate pain, including migraine headaches. 1

Regulatory Status and Formulation

• Diclofenac potassium 12.5 mg film-coated tablets were specifically developed for OTC use and are approved for short-term treatment of acute painful conditions of mild to moderate intensity. 1
• The standard prescription formulation is 50 mg tablets, which require a prescription. 2
• The OTC formulation uses the potassium salt for rapid absorption, with maximum plasma concentration reached within 30 minutes of administration. 1

Dosing for OTC Use

• Initial dose: Two tablets (2 × 12.5 mg = 25 mg) at symptom onset. 1
• Subsequent doses: One or two tablets every 4–6 hours as needed. 1
• Maximum daily dose: Six tablets (75 mg/day). 1
• Maximum treatment duration: 5 days for pain or 3 days for fever without medical consultation. 1

Efficacy in Migraine

• A single 25 mg dose (two 12.5 mg tablets) is at least as effective as ibuprofen 400 mg for acute migraine treatment. 1
• Diclofenac potassium 50 mg (prescription strength) provides pain-free response at 2 hours with an NNT of 6.2, headache relief at 2 hours with an NNT of 8.9, and sustained pain-free response at 24 hours with an NNT of 9.5. 3
• Diclofenac is recognized as one of four NSAIDs with randomized controlled trial evidence for efficacy in migraine (along with ibuprofen, naproxen sodium, and aspirin). 4

Specific Considerations for Perimenopausal Women with Migraine

• For infrequent migraine attacks in perimenopausal women, optimizing acute treatment with NSAIDs like diclofenac may be sufficient without requiring hormonal interventions. 5
• If migraine attacks are frequent or severe, continuous hormone replacement therapy or preventive migraine medications should be considered in addition to acute treatment. 5
• NSAIDs are appropriate for acute migraine management in perimenopausal women when used within recommended dosing limits to avoid medication-overuse headache. 5

Safety Profile

• The incidence of adverse events with diclofenac potassium at OTC doses is similar to ibuprofen and placebo. 1
• Adverse events are mostly mild and transient. 1, 3
• Long-term safety studies up to 3 months showed no evidence of hepatic injury or cardiovascular safety concerns at therapeutic doses. 1

Important Contraindications and Warnings

• Cardiovascular risk: Like all NSAIDs, diclofenac may cause serious cardiovascular events including myocardial infarction and stroke. 2
• Gastrointestinal risk: Serious GI ulceration and bleeding can occur without warning symptoms. 2
• Late pregnancy: Must be avoided as it causes premature closure of the ductus arteriosus. 2
• Medication-overuse headache: Use on ≥10 days per month can lead to chronic daily headache. 6

Clinical Pitfall to Avoid

• Patients must understand that exceeding the recommended 5-day treatment duration or using diclofenac on more than 10 days per month increases the risk of medication-overuse headache and progression to chronic migraine. 6, 1
• For frequent migraine attacks requiring regular acute medication use, preventive therapy should be initiated rather than continuing frequent OTC NSAID use. 6